Applicability of ISO14155 to Post Market Clinical Trials

In this video I’m going to briefly answer the following question:

 

“Is the ISO14155 applicable to the post-market stage of your clinical trial?”

 

Transcript:

In today’s video I’m going to briefly answer the following question:

“Is the ISO14155 applicable to the post-market stage of your clinical trial?”

 

In the latest 2020 version, Annex I brings welcome clarifications on the applicability of the requirements of this standard to the different clinical development stages.

It also includes a useful table for the planning and design of clinical investigation in all phases of the medical device lifecycle.

Annex I clearly emphasize on the fact that the ISO14155 is applicable to all clinical development stages, but also clearly points out which exemptions can be made when getting into the post-market stage and asks for a clear justification to be given for each exemption.

So yes, the ISO14155 is applicable to the clinical post-market stage whether or not with some possible exemptions.

Would you like to know which exemptions are allowed for the post-market stage, get yourself a copy of the standard or trained on it.

 

Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email

Other articles

Clinical Investigations

Safety reporting under MDR in The Netherlands part III

In this video, the following question is briefly answered: “When does vigilance reporting apply and who is responsible for this process?”   Transcript:   In this “trilogy” we talk about the safety reporting of different legal frameworks in The Netherlands.   The last 2 weeks we talked about safety reporting for clinical investigations that are

Clinical Investigations

Safety reporting under MDR in The Netherlands part II

In this video, the following question is briefly answered: “How do clinical investigations under article 82 comply with safety reporting in The Netherlands?”   Transcript:   Last week, we began looking at safety reporting. Today, we’re going to briefly focus on the following follow-up question:   How do clinical investigations under article 82 comply with

Scroll to Top